

# Kristine Griffett

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5624735/publications.pdf>

Version: 2024-02-01

19  
papers

805  
citations

758635

12  
h-index

794141

19  
g-index

20  
all docs

20  
docs citations

20  
times ranked

1524  
citing authors

#	ARTICLE	IF	CITATIONS
1	Nuclear Receptors and Their Selective Pharmacologic Modulators. <i>Pharmacological Reviews</i> , 2013, 65, 710-778.	7.1	207
2	Broad Anti-tumor Activity of a Small Molecule that Selectively Targets the Warburg Effect and Lipogenesis. <i>Cancer Cell</i> , 2015, 28, 42-56.	7.7	158
3	Pharmacological targeting of the mammalian clock regulates sleep architecture and emotional behaviour. <i>Nature Communications</i> , 2014, 5, 5759.	5.8	98
4	A Liver-Selective LXR Inverse Agonist That Suppresses Hepatic Steatosis. <i>ACS Chemical Biology</i> , 2013, 8, 559-567.	1.6	92
5	The LXR inverse agonist SR9238 suppresses fibrosis in a model of non-alcoholic steatohepatitis. <i>Molecular Metabolism</i> , 2015, 4, 353-357.	3.0	64
6	The mammalian clock and chronopharmacology. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 1929-1934.	1.0	31
7	Promiscuous activity of the LXR antagonist GSK2033 in a mouse model of fatty liver disease. <i>Biochemical and Biophysical Research Communications</i> , 2016, 479, 424-428.	1.0	27
8	Mitochondrial pyruvate carrier inhibitors improve metabolic parameters in diet-induced obese mice. <i>Journal of Biological Chemistry</i> , 2022, 298, 101554.	1.6	20
9	Development of novel liver X receptor modulators based on a 1,2,4-triazole scaffold. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2019, 29, 449-453.	1.0	17
10	Fructose Promotes Cytoprotection in Melanoma Tumors and Resistance to Immunotherapy. <i>Cancer Immunology Research</i> , 2021, 9, 227-238.	1.6	17
11	REV-ERB agonism improves liver pathology in a mouse model of NASH. <i>PLoS ONE</i> , 2020, 15, e0236000.	1.1	16
12	The Orphan Nuclear Receptor TLX Is a Receptor for Synthetic and Natural Retinoids. <i>Cell Chemical Biology</i> , 2020, 27, 1272-1284.e4.	2.5	15
13	Inhibition of Hepatotoxicity by a LXR Inverse Agonist in a Model of Alcoholic Liver Disease. <i>ACS Pharmacology and Translational Science</i> , 2018, 1, 50-60.	2.5	14
14	Emerging Role of Nuclear Receptors for the Treatment of NAFLD and NASH. <i>Metabolites</i> , 2022, 12, 238.	1.3	9
15	The role of REV-ERB in NASH. <i>Acta Pharmacologica Sinica</i> , 2022, 43, 1133-1140.	2.8	6
16	A two-hit model of alcoholic liver disease that exhibits rapid, severe fibrosis. <i>PLoS ONE</i> , 2021, 16, e0249316.	1.1	5
17	Antihyperlipidemic Activity of Gut-Restricted LXR Inverse Agonists. <i>ACS Chemical Biology</i> , 2022, , .	1.6	5
18	Synthesis and structure activity relationship of the first class of LXR inverse agonists. <i>Bioorganic Chemistry</i> , 2022, 119, 105540.	2.0	2

#	ARTICLE	IF	CITATIONS
19	Targeting Nuclear Receptors for Chronic Inflammatory Pain: A Potential Alternative. ACS Pharmacology and Translational Science, 2022, 5, 440-444.	2.5	2